85 related articles for article (PubMed ID: 32419536)
1. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:
Youn SW; Yu DY; Kim TY; Kim BS; Lee SC; Lee JH; Choe YB; Lee JH; Choi JH; Roh JY; Jo SJ; Lee ES; Shin MK; Lee MG; Jiang J; Lee Y
J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
[TBL] [Abstract][Full Text] [Related]
2. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
[TBL] [Abstract][Full Text] [Related]
3. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
Lebwohl MG; Merola JF; Rowland K; Miller M; Yang YW; Yu J; You Y; Chan D; Thaçi D; Langley RG
Br J Dermatol; 2023 Jul; 189(1):42-52. PubMed ID: 37022762
[TBL] [Abstract][Full Text] [Related]
4. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
[TBL] [Abstract][Full Text] [Related]
5. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
Orbai AM; Chakravarty SD; You Y; Shawi M; Yang YW; Merola JF
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2859-2868. PubMed ID: 37713133
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2.
Armstrong A; Eyerich K; Conrad C; Zhu Y; Yang YW; Miller M; You Y; Shen YK; Foley P; Griffiths CEM; Strober B
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1375-e1379. PubMed ID: 37415560
[No Abstract] [Full Text] [Related]
8. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A; Thaçi D; Papp KA; Ho V; Ghoreschi K; Kim BS; Miller M; Shen YK; You Y; Chan D; Yu J; Yang YW; Lebwohl MG; Gottlieb AB; Crowley J; Foley P
Br J Dermatol; 2023 Jul; 189(1):132-134. PubMed ID: 36944555
[No Abstract] [Full Text] [Related]
9. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
[TBL] [Abstract][Full Text] [Related]
10. Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
Egeberg A; Conrad C; Gorecki P; Wegner S; Buyze J; Acciarri L; Thaçi D
Dermatol Ther (Heidelb); 2024 Mar; 14(3):745-758. PubMed ID: 38485863
[TBL] [Abstract][Full Text] [Related]
11. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
Herranz-Pinto P; Alonso-Pacheco ML; Feltes-Ochoa R; Mayor-Ibarguren A; Servera-Negre G; Busto-Leis JM; Gonzalez-Fernández MA; Herrero-Ambrosio A
Clin Drug Investig; 2023 Jul; 43(7):517-527. PubMed ID: 37402097
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.
Haberman RH; MacFarlane KA; Catron S; Samuels J; Blank RB; Toprover M; Uddin Z; Hu J; Castillo R; Gong C; Qian K; Piguet V; Tausk F; Yeung J; Neimann AL; Gulliver W; Thiele RG; Merola JF; Ogdie A; Rahman P; Chakravarty SD; Eder L; Ritchlin CT; Scher JU
BMJ Open; 2022 Dec; 12(12):e063650. PubMed ID: 36564123
[TBL] [Abstract][Full Text] [Related]
13. Real-life data over 36 weeks of guselkumab treatment in psoriasis patients: A single-center study from Turkey.
Solak EÖ; Aba FC; Çınar SL; Kartal D; Borlu M
J Cosmet Dermatol; 2024 May; 23(5):1912-1917. PubMed ID: 38491736
[TBL] [Abstract][Full Text] [Related]
14. Better efficacy, lower recurrence rate and decreased CD8
Lu J; Huang D; Yang N; Qin H; Yu Y; Zhong X; Kong L; Jiang Y; Zhou J; Shi Y
Clin Immunol; 2024 Feb; 259():109899. PubMed ID: 38185271
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
Dermatol Ther (Heidelb); 2023 Feb; 13(2):487-504. PubMed ID: 36484917
[TBL] [Abstract][Full Text] [Related]
16. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study.
Puig L; Daudén E; Cuervas-Mons M; Novella C; Guisado C
J Eur Acad Dermatol Venereol; 2023 Aug; ():. PubMed ID: 37567861
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis.
Zheng J; Chen W; Yi X; Yu N; Ding Y; Gao Y
Front Med (Lausanne); 2023; 10():1285972. PubMed ID: 38162889
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial.
Rousel J; Bergmans ME; van der Meulen LWJ; Pagan L; de Bruin DT; de Kam ML; Klarenbeek NB; Bouwstra JA; Seyger MMB; van den Reek JMPA; Niemeyer-van der Kolk T; Rissmann R; van Doorn MBA;
J Am Acad Dermatol; 2024 Feb; 90(2):395-397. PubMed ID: 37804933
[No Abstract] [Full Text] [Related]
19. Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab.
Gracia Cazaña T; Riera Monroig J; Izu R; Yanguas I; Lorda Espés M; Sánchez Salas MP; García Gil MF; Navarro Bielsa A; Aldea Manrique B; Almenara Blasco M; García-Latasa de Araníbar FJ; Fuentelsaz V; Morales Callaghan A; Ara-Martín M
JAAD Int; 2024 Sep; 16():66-71. PubMed ID: 38774344
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of guselkumab in treatment of patients with psoriasis and coexisting hepatitis B or C: A multicenter prospective cohort study.
Huang YH; Yen JS; Li SH; Chiu HY
J Am Acad Dermatol; 2024 May; 90(5):1083-1086. PubMed ID: 38307145
[No Abstract] [Full Text] [Related]
[Next] [New Search]
